nach oben

Tumor Biology

Erschienen in:

02.09.2015 | Original Article

Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells

verfasst von: Ming Liu, Weiyi Zhang, Wei Tang, Yanjuan Wang, Xingzeng Zhao, Xiangyun Wang, Xin Qi, Jing Li

Erschienen in: Tumor Biology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Cyclopamine (CPM) showed promise as a human cancer chemotherapy agent. However, limitations such as stomach acid instability and low solubility impair its clinical application. In this study, we synthesized a novel CPM analogue, isocyclopamine (ICPM), which had comparative bioactivity with CPM and improved stability and solubility. ICPM reversed doxorubicin resistance and had potent synergy with doxorubicin in MCF-7/ADR cells. We further demonstrated that the synergistic mechanism was related to the increased intracellular accumulation of doxorubicin in the cells and the downregulation of the cancer stem-like cells via modulation on both ABCB1 and ABCG2 transporters with independence of Smoothened. The present study identified ICPM as a novel derivative of CPM with better stability and solubility, which provided a useful tool for the biological and medicinal studies, as well as a novel agent for the development of new cancer chemotherapy with improved efficacy.

Faneyte IF, Kristel PMP, Maliepaard M, Scheffer GL, Scheper RJ, Schellens JHM, et al. Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res. 2002;8(4):1068–74.PubMed

Vasconcelos FC, Cavalcanti GB, Silva KL, Ed M, Kwee JK, Rumjanek VM, et al. Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice. Leuk Res. 2007;31(4):445–54. doi:10.1016/j.leukres.2006.07.016.CrossRefPubMed

Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie J-P. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia, vol. 3. 1999.

Sotiropoulou PA, Christodoulou MS, Silvani A, Herold-Mende C, Passarella D. Chemical approaches to targeting drug resistance in cancer stem cells. Drug Discov Today. 2014;19(10):1547–62. http://dx.doi.org/10.1016/j.drudis.2014.05.002.CrossRefPubMed

Mannello F. Understanding breast cancer stem cell heterogeneity: time to move on to a new research paradigm. BMC Med. 2013;11(1):169.CrossRefPubMedPubMedCentral

Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci. 2011;1215:150–60. doi:10.1111/j.1749-6632.2010.05852.x.CrossRefPubMedPubMedCentral

Lee ST, Welch KD, Panter KE, Gardner DR, Garrossian M, Chang C-WT. Cyclopamine: from cyclops lambs to cancer treatment. J Agric Food Chem. 2014;62(30):7355–62. doi:10.1021/jf5005622.CrossRefPubMed

Tremblay M, McGovern K. Cyclopamine and its derivatives for cancer therapeutics. In: Xie J, editor. Hedgehog signaling activation in human cancer and its clinical implications. New York: Springer; 2011. p. 187–212.CrossRef

Sims-Mourtada J, Izzo JG, Ajani J, Chao KSC. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 2007;26(38):5674–9. http://www.nature.com/onc/journal/v26/n38/suppinfo/1210356s1.html.CrossRefPubMed

10.

Chai F, Zhou J, Chen C, Xie S, Chen X, Su P, et al. The hedgehog inhibitor cyclopamine antagonizes chemoresistance of breast cancer cells. Onco Targets Ther. 2013;6:1643–7.PubMedPubMedCentral

11.

Heretsch P, Buttner A, Tzagkaroulaki L, Zahn S, Kirchner B, Giannis A. Exo-cyclopamine—a stable and potent inhibitor of hedgehog signaling. Chem Commun. 2011;47(26):7362–4.CrossRef

12.

Wilson SR, Strand MF, Krapp A, Rise F, Petersen D, Krauss S. Hedgehog antagonist cyclopamine isomerizes to less potent forms when acidified. J Pharm Biomed Anal. 2010;52(5):707–13.CrossRefPubMed

13.

Moschner J, Chentsova A, Eilert N, Rovardi I, Heretsch P, Giannis A. Cyclopamine analogs bearing exocyclic methylenes are highly potent and acid-stable inhibitors of hedgehog signaling. Beilstein J Org Chem. 2013;9:2328–35. doi:10.3762/bjoc.9.267.CrossRefPubMedPubMedCentral

14.

Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55.CrossRefPubMed

15.

Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010;10(2):147–56.CrossRefPubMed

16.

Wang M, Wang Y, Zhong J. Side population cells and drug resistance in breast cancer. Mol Med Rep. 2015;30:10.

17.

Tsou S-H, Chen T-M, Hsiao H-T, Chen Y-H. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance. PLoS ONE. 2015;10(1):e0116747. doi:10.1371/journal.pone.0116747.CrossRefPubMedPubMedCentral

18.

Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol. 2012;83(8):1084–103. http://dx.doi.org/10.1016/j.bcp.2012.01.002.CrossRefPubMedPubMedCentral

19.

Balbuena J, Pachon G, Lopez-Torrents G, Aran JM, Castresana JS, Petriz J. ABCG2 is required to control the sonic hedgehog pathway in side population cells with stem-like properties. Cytometry A. 2011;79A(9):672–83. doi:10.1002/cyto.a.21103.

20.

Xia P. Surface markers of cancer stem cells in solid tumors. Curr Stem Cell Res Ther. 2014;9(2):102–11.CrossRefPubMed

21.

Schroeter A, Marko D. Resveratrol modulates the topoisomerase inhibitory potential of doxorubicin in human colon carcinoma cells. Molecules. 2014;19(12):20054–72.CrossRefPubMed

22.

Yu L, Wu WKK, Li ZJ, Liu QC, Li HT, Wu YC, et al. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-Glycoprotein activity. Mol Pharmacol. 2009;75(6):1364–73. doi:10.1124/mol.108.053546.CrossRefPubMed

23.

Videira M, Reis RL, Brito MA. Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. Biochim Biophys Acta. 2014;1846(2):312–25. http://dx.doi.org/10.1016/j.bbcan.2014.07.011.PubMed

24.

Zeino M, Paulsen MS, Zehl M, Urban E, Kopp B, Efferth T. Identification of new P-glycoprotein inhibitors derived from cardiotonic steroids. Biochem Pharmacol. 2015;93(1):11–24. http://dx.doi.org/10.1016/j.bcp.2014.10.009.CrossRefPubMed

25.

Singh S, Chitkara D, Mehrazin R, Behrman SW, Wake RW, Mahato RI. Chemoresistance in prostate cancer cells is regulated by miRNAs and hedgehog pathway. PLoS ONE. 2012;7(6):e40021. doi:10.1371/journal.pone.0040021.CrossRefPubMedPubMedCentral

26.

Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature. 2000;406(6799):1005–9. http://www.nature.com/nature/journal/v406/n6799/suppinfo/4061005a0_S1.html.CrossRefPubMed

27.

Wang C, Wu H, Katritch V, Han GW, Huang X-P, Liu W, et al. Structure of the human smoothened receptor 7TM bound to an antitumor agent. Nature. 2013;497(7449):338–43. doi:10.1038/nature12167.CrossRefPubMedPubMedCentral

28.

Ramaswamy B, Lu Y, Teng K-y, Nuovo G, Li X, Shapiro CL, et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res. 2012;72(19):5048–59. doi:10.1158/0008-5472.can-12-1248.CrossRefPubMed

29.

Zhang Y, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia (New York, NY). 2009;11(1):96–101.CrossRef

30.

Balbuena J, Pachon G, Lopez-Torrents G, Fan X, Castresana JS, Petriz J. Abstract 5049: cyclopamine modulates ABCG2 activity in glioblastoma side population cells. Cancer Res. 2011;71(8 Supplement):5049. doi:10.1158/1538-7445.am2011-5049.CrossRef

31.

Zhang X, Harrington N, Moraes R, Wu M-F, Hilsenbeck S, Lewis M. Cyclopamine inhibition of human breast cancer cell growth independent of smoothened (Smo). Breast Cancer Res Treat. 2009;115(3):505–21. doi:10.1007/s10549-008-0093-3.CrossRefPubMed

Titel: Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells
verfasst von: Ming Liu
Weiyi Zhang
Wei Tang
Yanjuan Wang
Xingzeng Zhao
Xiangyun Wang
Xin Qi
Jing Li
Publikationsdatum: 02.09.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 2/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3997-7

Springer Medizin

Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer

Altered expression of LINC-ROR in cancer cell lines and tissues

Regulation of β-catenin transcription activity by leupaxin in hepatocellular carcinoma

Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women

Presence of tumour high-endothelial venules is an independent positive prognostic factor and stratifies patients with advanced-stage oral squamous cell carcinoma

CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie